LOGIN  |  REGISTER
Terns Pharmaceuticals
Astria Therapeutics

Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

April 24, 2025 | Last Trade: US$60.08 3.18 -5.03

SAN FRANCISCO / Apr 24, 2025 / Business Wire / Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.

To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page